Novo Nordisk Shares Tumble on Grim 2026 Outlook, Sparking Investor Debate
The Danish pharmaceutical giant forecasts a potential double-digit sales decline for the year, citing pricing pressures and intensifying competition in the lucrative GLP-1 drug market.